MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - STRIDES PHARMA SCIENCE
SUN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
STRIDES PHARMA SCIENCE 
Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More
Current Valuations
| SUN PHARMA | STRIDES PHARMA SCIENCE | SUN PHARMA/ STRIDES PHARMA SCIENCE |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 28.6 | 15.6 | 183.3% | View Chart |
| P/BV | x | 2.5 | 0.9 | 267.9% | View Chart |
| Dividend Yield | % | 0.6 | 0.5 | 122.7% |
Financials
 SUN PHARMA  STRIDES PHARMA SCIENCE |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-19 |
STRIDES PHARMA SCIENCE Mar-18 |
SUN PHARMA/ STRIDES PHARMA SCIENCE |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 679 | 1,147 | 59.2% | |
| Low | Rs | 375 | 642 | 58.5% | |
| Sales per share (Unadj.) | Rs | 121.1 | 317.2 | 38.2% | |
| Earnings per share (Unadj.) | Rs | 13.4 | 7.8 | 170.5% | |
| Cash flow per share (Unadj.) | Rs | 20.7 | 25.1 | 82.6% | |
| Dividends per share (Unadj.) | Rs | 2.75 | 2.00 | 137.5% | |
| Dividend yield (eoy) | % | 0.5 | 0.2 | 233.3% | |
| Book value per share (Unadj.) | Rs | 172.6 | 274.3 | 62.9% | |
| Shares outstanding (eoy) | m | 2,399.26 | 89.50 | 2,680.7% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 4.4 | 2.8 | 154.3% | |
| Avg P/E ratio | x | 39.4 | 114.0 | 34.6% | |
| P/CF ratio (eoy) | x | 25.5 | 35.7 | 71.4% | |
| Price / Book Value ratio | x | 3.1 | 3.3 | 93.6% | |
| Dividend payout | % | 20.6 | 25.5 | 80.6% | |
| Avg Mkt Cap | Rs m | 1,264,650 | 80,058 | 1,579.7% | |
| No. of employees | `000 | 17.5 | 2.5 | 698.1% | |
| Total wages/salary | Rs m | 59,671 | 4,341 | 1,374.7% | |
| Avg. sales/employee | Rs Th | 16,608.1 | 11,325.8 | 146.6% | |
| Avg. wages/employee | Rs Th | 3,409.6 | 1,731.4 | 196.9% | |
| Avg. net profit/employee | Rs Th | 1,833.8 | 280.1 | 654.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 290,659 | 28,394 | 1,023.7% | |
| Other income | Rs m | 10,255 | 941 | 1,090.3% | |
| Total revenues | Rs m | 300,914 | 29,334 | 1,025.8% | |
| Gross profit | Rs m | 63,076 | 3,965 | 1,590.7% | |
| Depreciation | Rs m | 17,533 | 1,540 | 1,138.2% | |
| Interest | Rs m | 5,553 | 1,962 | 282.9% | |
| Profit before tax | Rs m | 50,246 | 1,403 | 3,580.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | -168 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | -12,144 | -436 | 2,786.6% | |
| Tax | Rs m | 6,009 | 97 | 6,175.5% | |
| Profit after tax | Rs m | 32,093 | 702 | 4,571.0% | |
| Gross profit margin | % | 21.7 | 14.0 | 155.4% | |
| Effective tax rate | % | 12.0 | 6.9 | 172.5% | |
| Net profit margin | % | 11.0 | 2.5 | 446.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 310,692 | 24,836 | 1,251.0% | |
| Current liabilities | Rs m | 173,396 | 18,993 | 912.9% | |
| Net working cap to sales | % | 47.2 | 20.6 | 229.5% | |
| Current ratio | x | 1.8 | 1.3 | 137.0% | |
| Inventory Days | Days | 99 | 71 | 139.6% | |
| Debtors Days | Days | 112 | 113 | 98.4% | |
| Net fixed assets | Rs m | 232,477 | 34,289 | 678.0% | |
| Share capital | Rs m | 2,399 | 895 | 268.1% | |
| "Free" reserves | Rs m | 411,691 | 23,651 | 1,740.7% | |
| Net worth | Rs m | 414,091 | 24,546 | 1,687.0% | |
| Long term debt | Rs m | 15,226 | 15,513 | 98.1% | |
| Total assets | Rs m | 646,938 | 65,437 | 988.6% | |
| Interest coverage | x | 10.0 | 1.7 | 585.9% | |
| Debt to equity ratio | x | 0 | 0.6 | 5.8% | |
| Sales to assets ratio | x | 0.4 | 0.4 | 103.5% | |
| Return on assets | % | 5.8 | 4.1 | 142.9% | |
| Return on equity | % | 7.8 | 2.9 | 271.0% | |
| Return on capital | % | 10.2 | 6.9 | 147.5% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 66,025 | 15,697 | 420.6% | |
| Fx outflow | Rs m | 38,610 | 735 | 5,250.2% | |
| Net fx | Rs m | 27,415 | 14,962 | 183.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 21,965 | 1,871 | 1,174.1% | |
| From Investments | Rs m | -6,813 | 5,826 | -116.9% | |
| From Financial Activity | Rs m | -27,305 | -10,157 | 268.8% | |
| Net Cashflow | Rs m | -8,442 | -2,615 | 322.8% | |
Share Holding
| Indian Promoters | % | 63.7 | 27.7 | 230.0% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.1 | 37.8 | 13.6% | |
| FIIs | % | 23.0 | 8.6 | 267.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.3 | 25.9 | 32.0% | |
| Shareholders | 133,026 | 56,241 | 236.5% | ||
| Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: ALEMBIC LTD SHASUN PHARMA PFIZER FDC LTD. AUROBINDO PHARMA
Compare SUN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)
Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.
Related Views on News
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)
Jul 31, 2019 | Updated on Jul 31, 2019For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsMost Popular
Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)
Sep 5, 2019Everyone dreams of owning a business. Here is your chance.
7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)
Sep 5, 2019The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?
Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)
Sep 4, 2019Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
MoreSUN PHARMA SHARE PRICE
Sep 17, 2019 10:01 AM
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.